The Legacy Institutional Biosafety Committee (IBC) is responsible for the review and approval of all research involving recombinant or synthetic nucleic acid molecules (e.g., rDNA) that utilize Legacy Research Institute facilities, and is available to provide review and approval for this type of research that utilizes any Legacy Health facility, resource or patients. This oversight includes laboratory rDNA research and human gene therapy research. The IBC also reviews all research projects at the Legacy Research Institute that involve non-recombinant risk group 2 and higher infectious agents.

Instructions for starting the IBC review process:

• Request an IBC Protocol application form from the research laboratory safety specialist at jost@lhs.org. He will forward the required form(s) and instructions.
• Complete the form and have it signed by the principal investigator (PI).
• Return the form to the research laboratory safety specialist.

If you require guidance for completing the form, please contact the research laboratory safety specialist.

Note that human gene therapy research is also subject to IRB oversight, and the agent used requires prior FDA approval.

IBC Contact: John Ost, MAT, Research Laboratory Safety Specialist
Telephone: (503) 413-5409
Email: jost@lhs.org

Resources:

1. NIH Office of Science Policy (OSP)
2. NIH Guidelines for Research Involving Recombinant & Synthetic Nucleic Acids